Vanguard Group Inc Talaris Therapeutics, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.68 - $3.22 $168,183 - $202,071	62,755 Added 6.05%	1,100,626 $3.09 Million
Q2 2023 Aug 14, 2023	SELL	$1.78 - $3.2 $154,995 - $278,643	-87,076 Reduced 7.74%	1,037,871 $3.16 Million
Q1 2023 May 15, 2023	BUY	$1.09 - $2.09 $79,718 - $152,854	73,136 Added 6.95%	1,124,947 $2.11 Million
Q4 2022 Feb 10, 2023	BUY	$0.94 - $1.64 $32,724 - $57,093	34,813 Added 3.42%	1,051,811 $1.07 Million
Q3 2022 Nov 14, 2022	SELL	$2.3 - $5.03 $2,592 - $5,668	-1,127 Reduced 0.11%	1,016,998 $2.68 Million
Q2 2022 Aug 12, 2022	SELL	$4.51 - $9.85 $56,902 - $124,277	-12,617 Reduced 1.22%	1,018,125 $4.59 Million
Q1 2022 May 13, 2022	SELL	$6.89 - $16.56 $551 - $1,324	-80 Reduced 0.01%	1,030,742 $10.1 Million
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $7.75 Million - $10.8 Million	636,644 Added 161.51%	1,030,822 $15.8 Million
Q3 2021 Nov 12, 2021	BUY	$11.61 - $15.99 $38,916 - $53,598	3,352 Added 0.86%	394,178 $5.35 Million
Q2 2021 Aug 13, 2021	BUY	$12.25 - $18.61 $4.79 Million - $7.27 Million	390,826 New	390,826 $5.74 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.